Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | TSHR | P16473 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Hexanol SCHEMBL9796428 | 1.00 | ALDH1A1 (0.77) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Dodecanol SCHEMBL27744843 | 1.00 | ALDH1A1 (0.77) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Octacosanol SCHEMBL20477539 | 1.00 | ALDH1A1 (0.77) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Nonanol SCHEMBL12275209 | 1.00 | ALDH1A1 (0.77) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Octanol SCHEMBL467972 | 1.00 | ALDH1A1 (0.77) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| 1-Hexanol SCHEMBL28327028 | 0.97 | ALDH1A1 (0.72) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| 1-Pentanol SCHEMBL11280714 | 0.97 | SMN1; SMN2 (0.75) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| 1-Pentanol SCHEMBL28908456 | 0.94 | SMN1; SMN2 (0.71) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Hexane SCHEMBL28322647 | 0.91 | ALDH1A1 (0.69) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| SCHEMBL25421234 | 0.87 | LMNA (1.00) | ALDH1A1TSHRLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0960121-B1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT DORTE (DK) | 2005-11-30 | — | — | EP | disclosed |
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6710164-B1 | COMPRISING AT LEAST ONE C1-C8 ALKYLAMINE SIDE CHAIN | NIELSEN PETER E (DK) | 2004-03-23 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-0960121-A4 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT DORTE (DK) | 2003-05-28 | — | — | EP | disclosed |
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | disclosed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1003480-A4 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | NIELSEN PETER EIGIL (DK) | 2002-04-17 | — | — | EP | disclosed |
| EP-1003480-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | NIELSEN, Peter Eigil (DK) | 2000-05-31 | — | — | EP | disclosed |
| EP-0960121-A1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT, Dorte (DK) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998053801-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5766855-A | Peptide nucleic acids having enhanced binding affinity and sequence specificity | BUCHARDT OLE (DK) | 1998-06-16 | — | — | US | disclosed |
| WO-1998003542-A1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT, DORTE (DK) | 1998-01-29 | — | — | WO | disclosed |
| US-5274129-A | Hydroxamic acid crown ethers | IDAHO RESEARCH FOUNDATION, INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5225173-A | Chelation, crown ethers | IDAHO RESEARCH FOUNDATION, INC. (US) | 1993-07-06 | — | — | US | disclosed |
| US-5162509-A | Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0462206-A1 | EXPANDED PORPHYRINS: LARGE PORPHYRIN-LIKE TRIPYRROLEDIMETHINE-DERIVED MACROCYCLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-12-27 | — | — | EP | disclosed |
| WO-1990010633-A1 | EXPANDED PORPHYRINS: LARGE PORPHYRIN-LIKE TRIPYRROLEDIMETHINE-DERIVED MACROCYCLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | TPMT, CD47, THPO | ALDH1A1 3159/4885TSHR 662/4885LMNA 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.